Safety of Oxi-nase Spray in G6PD Deficiency and Mild Thalassemia

Patient Risk Profile

• The severity of hemolytic risk varies by genetic variant, with Mediterranean variants (Gdmed) causing more severe reactions than African variants (GdA-) 1, 2
• Topical nasal medications with minimal systemic absorption pose negligible risk even in G6PD-deficient patients 3

Monitoring and Precautions

• Watch for signs of hemolysis: jaundice, dark urine, fatigue, and pallor, especially when starting any new medication 1, 2, 4
• For patients with Mediterranean or Southeast Asian descent, screening for G6PD deficiency severity is recommended before using any potentially oxidative medications 1, 2